Kwang-Woo Chun

This inventor holds 3 USPTO granted patents, plus 1 CIPO patent and 1 EPO patent. Top assignee: Je Il Pharmaceutical Co., Ltd.. Active years: 2012-2014.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Kwang-Woo Chun. Retrieved from https://idiyas.com/inventor/kwang-woo-chun

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 3

% Patents Active = 66.7

CIPO Patents = 1

EPO Patents = 1 (Patent Applications = 2)

Average Co-Inventor Count = 6.8

ph-index = 1

Forward Citations = 45(Granted Patents)

Company Filing History:

3 out of 9

Je Il Pharmaceutical Co., Ltd.

patents

Years Active: 2012-2014

Loading Chart...

3 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8906395 - Pharmaceutical composition in which solubility of partially soluble tricyclic derivative is improved (2014-12-09),

2. 8815891 - Tricyclic derivative or pharmaceutically acceptable salts thereof, preparation method thereof, and pharmaceutical composition containing the same (2014-08-26),

3. 8334277 - {4-[2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl]phenoxy}phosphate or a pharmaceutically acceptable salt thereof, a production method therefor and a pharmaceutical composition for preventing and treating central nervous system disorders containing the same as an active component (2012-12-18),

Title: Kwang-Woo Chun: Innovator in Pharmaceutical Composition

Introduction

Kwang-Woo Chun is a notable inventor based in Yongin-si, South Korea. He has made significant contributions to the field of pharmaceuticals, particularly in improving the solubility of tricyclic derivatives. With a total of three patents to his name, Chun's work is paving the way for advancements in medical treatments.

Latest Patents

Chun's latest patents focus on innovative pharmaceutical compositions. One of his key inventions is a pharmaceutical composition that improves the solubility of partially soluble tricyclic derivatives. This composition utilizes lipid nanoparticles that include phospholipids, cholesterol, and ionic lipids. The invention allows for high concentrations of the tricyclic derivative to be solubilized without harmful solubilization aids. This is particularly beneficial for injection use, as it maintains improved solubility and stability over time. Another significant patent involves a novel tricyclic derivative that exhibits efficient inhibitory activity against poly(ADP-ribose) polymerases (PARP). This derivative is aimed at treating various diseases, including neuropathic pain, neurodegenerative diseases, and cancer.

Career Highlights

Kwang-Woo Chun is currently associated with Je Il Pharmaceutical Co., Ltd., where he continues to innovate in the pharmaceutical sector. His work has garnered attention for its potential impact on drug development and therapeutic applications.

Collaborations

Chun collaborates with esteemed colleagues such as Myung-Hwa Kim and In-Hae Ye, contributing to a dynamic research environment that fosters innovation.

Conclusion

Kwang-Woo Chun's contributions to pharmaceutical compositions highlight his role as a leading inventor in the field. His innovative approaches to improving drug solubility and efficacy are set to make a lasting impact on medical treatments.

Profile summary based on public USPTO records.